Qualified protein degradation is currently being explored as an alternative tactic in cancer, whereby the organic protein degradation program is co-opted for therapeutic uses. Not too long ago formulated novel molecules known as proteolysis-focusing on chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. One ligand binds https://www.directivepublications.org/journal-of-clinical-breast-cancer/